Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2023

Van Emmenis L, Ku S-, Gayvert K, Branch JR, Brady NJ, Basu S, et al. The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer. Cancer Res Commun. 2023;3(8):1447-1459.

Osman AE, Mencia-Trinchant N, Saygin C, Moma L, Kim A, Housman G, et al. Paired bone marrow and peripheral blood samples demonstrate lack of widespread dissemination of some CH clones. Blood Adv. 2023;7(9):1910-1914.

Ma C, Zhou Y, Fanelli GN, Stopsack KH, Fiorentino M, Zadra G, et al. The Prostate Stromal Transcriptome in Aggressive and Lethal Prostate Cancer. Mol Cancer Res. 2023;21(3):253-260.

Assaad MA, Shin N, Sigouros M, Manohar J, Antysheva Z, Kotlov N, et al. Deciphering the origin and therapeutic targets of cancer of unknown primary: a case report that illustrates the power of integrative whole-exome and transcriptome sequencing analysis. Front Oncol. 2023;13:1274163.

Xu Z, Yang HS, Liu L, Meng L, Lu Y, Han L, et al. Elevated levels of renal function tests conferred increased risks of developing various pregnancy complications and adverse perinatal outcomes: insights from a population-based cohort study. Clin Chem Lab Med. 2023;61(10):1760-1769.

Sciascia S, Yazdany J, Moroni G, Becker JU, Seshan SV, Andrade D, et al. Clinical-Pathological Characteristics of Renal Injuries Identify Different Clusters in Patients With Antiphospholipid Antibodies. Kidney Int Rep. 2023;8(4):754-763.

Pianko MJ, Tiutan T, Derkach A, Flynn J, Salvatore SP, Jaffer-Sathick I, et al. Assessment of renal outcome following therapy in monoclonal immunoglobulin deposition disease: Emphasizing the need for a consensus approach. Am J Hematol. 2023;98(3):421-431.

Giantini-Larsen AM, Kharas N, Pisapia D, Schwartz TH. Histology of high-grade glioma samples resected using 5-ALA fluorescent headlight and loupe combination. Acta Neurochir (Wien). 2023;165(2):567-575.

Xu Z, Marchionni L, Wang S. MultiNEP: a multi-omics network enhancement framework for prioritizing disease genes and metabolites simultaneously. Bioinformatics. 2023;39(6).

Wang M, Wisniewski CA, Xiong C, Chhoy P, Goel HL, Kumar A, et al. Therapeutic blocking of VEGF binding to neuropilin-2 diminishes PD-L1 expression to activate antitumor immunity in prostate cancer. Sci Transl Med. 2023;15(694):eade5855.